The Application of Metabolomics in Pituitary Adenoma Studies: A Review of Progress and Challenges
|
A Bahramirad , A Vasheghani Farahani , A Khosravi , A Sarrafi , S.M Tavangar , M Hedayati , S.A Razavi  |
Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Molecular Biology, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I.R. Iran , s.a.razavi@endocrine.ac.ir |
|
Abstract: (87 Views) |
Metabolomics, a novel discipline within the omics sciences, focuses on the comprehensive analysis of metabolites in biological systems. Pituitary adenomas are benign tumors of the anterior pituitary gland and rank among the most common brain tumors after gliomas and meningiomas. Metabolomics is a powerful tool that can significantly enhance our understanding of various aspects of pituitary adenomas. Recent advancements in metabolomic techniques have the potential to aid in the diagnosis of pituitary adenomas and to elucidate the metabolic alterations associated with tumorigenesis. By analyzing metabolic profiles, potential biomarkers for diagnosis and prognosis can be identified, thereby facilitating personalized treatment strategies. Moreover, integrating metabolomics with other omics technologies provides a holistic view of tumor biology and uncovers complex metabolic pathways involved in the progression of pituitary adenomas. However, challenges remain, including the need for standardized methodologies, the complexity of data interpretation, and the integration of metabolomic findings with clinical outcomes. This review examines the current state of metabolomics research in pituitary adenomas, highlights its potential to transform our understanding of these tumors and improve patient outcomes, and discusses the existing barriers to its broader application. |
|
Keywords: Metabolomics, Metabolite, Pituitary adenoma, Pituitary tumor, Biomarker |
|
Full-Text [PDF 908 kb]
(58 Downloads)
|
Type of Study: Review |
Subject:
Biochemistry Received: 2025/01/21 | Accepted: 2025/05/13 | Published: 2025/03/30
|
|
|
|
|
Add your comments about this article |
|
|